Medpace Holdings faces lawsuit over alleged misleading growth info causing inflated stock prices.

Kuehn Law is investigating Medpace Holdings, Inc. for allegedly misleading shareholders by misrepresenting key business metrics like backlog cancellations and growth projections. The lawsuit claims Medpace provided overly optimistic growth expectations, leading investors to buy stock at inflated prices. Shareholders who bought stock before April 22, 2025, are encouraged to contact the law firm to potentially enforce their rights. This case highlights risks of inaccurate corporate disclosures affecting investor decisions and stock valuations.